单一和多重耐药机制对细菌对美罗胺的反应的影响
Dominika T Fuhs1, Sara Cortés-Lara2, Jessica R Tait1
1Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
概括
在Pseudomonas aeruginosa中,美罗胺耐药性是复杂的. 一种新的定量和系统药理 (QSP) 模型比传统方法更好地预测细菌杀死和耐药性,并考虑了基线耐药性机制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 基因组学就是基因组学.
背景情况:
- 梅罗是治疗Pseudomonas aeruginosa感染的关键抗生素.
- 传统的剂量策略依赖于最小抑制度 (fT>MIC) 以上的时间.
- 基线耐药机制可以影响美罗的疗效和耐药性的出现.
研究的目的:
- 描述不同基线耐药机制如何影响细菌杀死和耐药性.
- 评估FT>MIC对这些结果的预测能力.
- 开发一个量化和系统药理学 (QSP) 模型,用于P. aeruginosa.中的美罗胺反应.
主要方法:
- 在空洞纤维感染模型中利用了七种具有不同抵抗机制的同源P. aeruginosa菌株.
- 模拟的美罗胺药理动力学特征,用于不同的剂量方案.
- 在细菌活力数据和耐药群体的全基因组测序上采用QSP建模.
主要成果:
- fT>MIC值未能预测具有特定基线抗性机制 (例如,OprD损失,ampD/mexR双击) 的菌株的抗性抑制.
- 基线耐药机制显著影响了细菌结果,独立于MIC.
- 基因组分析确定了先前存在的耐药亚群和特定突变 (mexR, oprD, lysS, argS),推动了耐药性的出现.
结论:
- 开发的QSP模型有效地描述了多个菌株和耐药性机制的细菌结果.
- 与fT>MIC相比,QSP建模在P. aeruginosa治疗中提供了优越的预测能力,具有多样化的耐药性.
相关概念视频
Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
Antibiotic Selection
52.7K
Overview
52.7K
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


